Trial Information

Summary: A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects with Hypertension

A phase 3 study to evaluate the efficacy of triple therapy (Benicar, Lotrel and Hydrochlorothiazide). This trial has four treatment arms. There is no placebo. There is up to a 3 week washout period of current hypertensive medications. This study is 57 weeks with 13 clinic visits.

Patient Inclusion Criteria:

• Male or female
• Age 18 year or older

Patient Exclusion Criteria:

• Uncontrolled Type 1 or Type 2 Diabetes
• Chronic Atrial Fibrillation or Flutter
• History of hypertensive encephalopathy, stroke or transient ischemic attack (TIA)
• Any history of congestive heart failure (CHF)
• History of secondary hypertension including renal disease or Cushing's syndrome
• History of myocardial infarction, coronary artery bypass graft and/or unstable angina within the past 6 months

If you would like to learn more about participating in this study, please send an e-mail message using the form below.